Suppr超能文献

美国局限性前列腺癌的当前临床表现与治疗

Current clinical presentation and treatment of localized prostate cancer in the United States.

作者信息

Mahmood Usama, Levy Lawrence B, Nguyen Paul L, Lee Andrew K, Kuban Deborah A, Hoffman Karen E

机构信息

Departments of Radiation Oncology, M.D. Anderson Cancer Center, Houston, Texas, and Brigham and Women's Hospital, Harvard Medical School (PLN), Boston, Massachusetts.

Departments of Radiation Oncology, M.D. Anderson Cancer Center, Houston, Texas, and Brigham and Women's Hospital, Harvard Medical School (PLN), Boston, Massachusetts.

出版信息

J Urol. 2014 Dec;192(6):1650-6. doi: 10.1016/j.juro.2014.06.017. Epub 2014 Jun 12.

Abstract

PURPOSE

SEER recently released patient Gleason scores at biopsy/transurethral resection of the prostate. For the first time this permits accurate assessment of prostate cancer presentation and treatment according to clinical factors at diagnosis.

MATERIALS AND METHODS

We used the SEER database to identify men diagnosed with localized prostate cancer in 2010 who were assigned NCCN(®) risk based on clinical factors. We identified sociodemographic factors associated with high risk disease and analyzed the impact of these factors along with NCCN risk on local treatment.

RESULTS

Of the 42,403 men identified disease was high, intermediate and low risk in 38%, 40% and 22%, respectively. On multivariate analysis patients who were older, nonwhite, unmarried or living in a county with a higher poverty rate were more likely to be diagnosed with high risk disease (each p <0.05). Of the 38,634 men in whom prostate cancer was the first malignancy 23% underwent no local treatment, 40% were treated with prostatectomy, 36% received radiation therapy and 1% underwent local tumor destruction, predominantly cryotherapy. On multivariate analysis patients who were older, black, unmarried or living in a county with a higher poverty rate, or who had low risk disease were less likely to receive local treatment (each p <0.05).

CONCLUSIONS

Our analysis provides information on the current clinical presentation and treatment of localized prostate cancer in the United States. Nonwhite and older men living in a county with a higher poverty rate were more likely to be diagnosed with high risk disease and less likely to receive local treatment.

摘要

目的

监测、流行病学与最终结果(SEER)项目最近公布了前列腺活检/经尿道前列腺切除术患者的 Gleason 评分。这首次使得能够根据诊断时的临床因素对前列腺癌的表现和治疗进行准确评估。

材料与方法

我们使用 SEER 数据库来识别 2010 年被诊断为局限性前列腺癌且根据临床因素被指定为美国国立综合癌症网络(NCCN)风险分级的男性。我们确定了与高危疾病相关的社会人口统计学因素,并分析了这些因素以及 NCCN 风险分级对局部治疗的影响。

结果

在识别出的 42403 名男性中,疾病为高危、中危和低危的分别占 38%、40%和 22%。多因素分析显示,年龄较大、非白人、未婚或生活在贫困率较高县的患者更有可能被诊断为高危疾病(各 p<0.05)。在 38634 名前列腺癌为首发恶性肿瘤的男性中,23%未接受局部治疗,40%接受了前列腺切除术,36%接受了放射治疗,1%接受了局部肿瘤破坏治疗,主要是冷冻治疗。多因素分析显示,年龄较大、黑人、未婚或生活在贫困率较高县的患者,或患有低危疾病的患者接受局部治疗的可能性较小(各 p<0.05)。

结论

我们的分析提供了关于美国局限性前列腺癌当前临床表现和治疗的信息。生活在贫困率较高县的非白人和老年男性更有可能被诊断为高危疾病,且接受局部治疗的可能性较小。

相似文献

1
Current clinical presentation and treatment of localized prostate cancer in the United States.
J Urol. 2014 Dec;192(6):1650-6. doi: 10.1016/j.juro.2014.06.017. Epub 2014 Jun 12.
4
A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer.
Int Urol Nephrol. 2015 Oct;47(10):1629-34. doi: 10.1007/s11255-015-1096-8. Epub 2015 Sep 2.
9
Physician variation in management of low-risk prostate cancer: a population-based cohort study.
JAMA Intern Med. 2014 Sep;174(9):1450-9. doi: 10.1001/jamainternmed.2014.3021.
10
What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
J Urol. 2008 Oct;180(4):1330-4; discussion 1334-5. doi: 10.1016/j.juro.2008.06.019. Epub 2008 Aug 15.

引用本文的文献

1
Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer.
Int J Part Ther. 2024 Apr 24;12:100015. doi: 10.1016/j.ijpt.2024.100015. eCollection 2024 Jun.
2
Control of the activity of CAR-T cells within tumours via focused ultrasound.
Nat Biomed Eng. 2021 Nov;5(11):1336-1347. doi: 10.1038/s41551-021-00779-w. Epub 2021 Aug 12.
6
Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database.
Adv Radiat Oncol. 2018 Jan 31;3(2):170-180. doi: 10.1016/j.adro.2017.12.008. eCollection 2018 Apr-Jun.
7
Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution.
J Cancer. 2018 Apr 19;9(10):1797-1803. doi: 10.7150/jca.25113. eCollection 2018.
8
Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer.
Oncotarget. 2017 Dec 7;9(12):10203-10210. doi: 10.18632/oncotarget.23011. eCollection 2018 Feb 13.
9
Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer.
Front Oncol. 2017 Nov 23;7:275. doi: 10.3389/fonc.2017.00275. eCollection 2017.

本文引用的文献

1
Cancer statistics, 2013.
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
2
Clinical decisions. Prostate cancer screening--polling results.
N Engl J Med. 2012 Oct 25;367(17):e25. doi: 10.1056/NEJMclde1212034.
3
Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
J Urol. 2012 Jun;187(6):2026-31. doi: 10.1016/j.juro.2012.01.070. Epub 2012 Apr 11.
5
Understanding variation in primary prostate cancer treatment within the Veterans Health Administration.
Urology. 2012 Mar;79(3):537-45. doi: 10.1016/j.urology.2011.11.013. Epub 2012 Jan 13.
6
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
Lancet. 2011 Dec 17;378(9809):2104-11. doi: 10.1016/S0140-6736(11)61095-7. Epub 2011 Nov 2.
7
Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.
Ann Intern Med. 2011 Dec 6;155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375. Epub 2011 Oct 7.
8
Racial differences in PSA screening interval and stage at diagnosis.
Cancer Causes Control. 2010 Jul;21(7):1071-80. doi: 10.1007/s10552-010-9535-4. Epub 2010 Mar 24.
9
Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.
J Clin Oncol. 2010 Feb 20;28(6):1069-74. doi: 10.1200/JCO.2009.26.2469. Epub 2010 Jan 25.
10
An update of the Gleason grading system.
J Urol. 2010 Feb;183(2):433-40. doi: 10.1016/j.juro.2009.10.046. Epub 2009 Dec 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验